Tirzepatide studies
4,040 journal papers mention Tirzepatide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Tirzepatide is safe, effective or approved for any use.
- Papers
- 4,040
- 3,147 articles, 893 reviews
- Earliest paper
- 2017
- Most papers in 2026 (1,675)
- Open access
- 65%
- free to read somewhere
- Reviews
- 22%
- of all papers listed
What kind of studies
Of 2,729 papers in PubMed that mention Tirzepatide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials134
- Other clinical trials11
- Meta-analyses and systematic reviews224
- Other reviews998
- Case reports169
- Animal studies only78
- Studies in humans1,479
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Tirzepatide in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 310
- Completed
- 92
- Ongoing or planned
- 207
- Phase 1
- 41
- Phase 2
- 80
- Phase 3
- 60
- Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
NCT07832084Not yet recruitingPhase 4started 2026-12
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458Not yet recruitingPhase 3started 2026-11
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432Not yet recruitingPhase 3started 2026-12
- Tirzepatide for Treatment of CCCA
NCT07734870RecruitingPhase 2started 2026-09-15
- Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea
NCT07846865Not yet recruitingPhase 2 / Phase 3started 2026-10-01
The five most recently updated studies. See all 310 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2017 to 2026, peak 1,675 papers in a year. The latest year may still be incomplete.
Where it is published
- Diabetes258 papers
- Diabetes Obesity and Metabolism177 papers
- Cureus119 papers
- Journal of the Endocrine Society72 papers
- Endocrine Practice46 papers
The papers
Most citedName in the title
- Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad et al. · New England Journal of Medicine · 2022
Randomized trial · Phase 3Open access3,840 citationsRead the open copy →
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie Jane Davies, Julio Rosenstock et al. · New England Journal of Medicine · 2021
Randomized trial · Phase 3Open access · CC BY2,099 citationsRead the open copy →
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías et al. · The Lancet · 2021
Randomized trial · Phase 31,080 citations
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Milton Packer, Michael R. Zile, Christopher M. Kramer et al. · New England Journal of Medicine · 2024
Randomized trial · Phase 31,015 citations
- Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Rohit Seth Loomba, Mark L. Hartman, Eric Lawitz et al. · New England Journal of Medicine · 2024
Randomized trial · Phase 21,009 citations
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Atul Malhotra, Ronald R. Grunstein, Ingo Fietze et al. · New England Journal of Medicine · 2024
Randomized trial · Phase 3Open access874 citationsRead the open copy →
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Louis J. Aronne, Naveed A. Sattar, Deborah Bade Horn et al. · JAMA · 2023
Randomized trial · Phase 3Open access861 citationsRead the open copy →
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
William Timothy Garvey, Juan P Frias, Ania M. Jastreboff et al. · The Lancet · 2023
Randomized trial · Phase 3Open access792 citationsRead the open copy →
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato, Steven E. Kahn, Imre J. Pavo et al. · The Lancet · 2021
Clinical trial · Phase 3684 citations
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard H. Ludvik, Francesco Giorgino, Esteban Jódar et al. · The Lancet · 2021
Randomized trial · Phase 3642 citations
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Louis J. Aronne, Deborah Bade Horn, Carel Wynand le Roux et al. · New England Journal of Medicine · 2025
Clinical trial · Phase 3Open access · CC BY-NC-ND635 citationsRead the open copy →
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Dominik B. Dahl, Yukiko Onishi, Paul C. Norwood et al. · JAMA · 2022
Randomized trial · Phase 3Open access598 citationsRead the open copy →
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe et al. · JCI Insight · 2020
Animal studyOpen access · CC BY541 citationsRead the open copy →
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth J. Cusi, Laura Fernández Landó et al. · The Lancet Diabetes & Endocrinology · 2022
Randomized trial513 citations
- Tirzepatide for Obesity Treatment and Diabetes Prevention
Ania M. Jastreboff, Carel Wynand le Roux, Adam Stefański et al. · New England Journal of Medicine · 2024
Randomized trial · Phase 3462 citations
- Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
Thomas A. Wadden, Ariana M. Chao, Sriram Machineni et al. · Nature Medicine · 2023
Randomized trial · Phase 3Open access · CC BY446 citationsRead the open copy →
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael Albrecht Nauck, David A. D’Alessio · Cardiovascular Diabetology · 2022
ReviewOpen access · CC BY407 citationsRead the open copy →
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman, Arun Jayant Sanyal, Rohit Seth Loomba et al. · Diabetes Care · 2020
Randomized trial · Phase 2Open access351 citationsRead the open copy →
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed A. Sattar, Darren K. McGuire, Imre J. Pavo et al. · Nature Medicine · 2022
Meta-analysisOpen access · CC BY346 citationsRead the open copy →
- Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Melissa K. Thomas, Amir Nikooienejad, Ross Bray et al. · The Journal of Clinical Endocrinology & Metabolism · 2020
Randomized trialOpen access · CC BY-NC-ND344 citationsRead the open copy →
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Patricia J. Rodriguez, Brianna M Goodwin Cartwright, Samuel Gratzl et al. · JAMA Internal Medicine · 2024
Study in humansOpen access · CC BY-NC-ND335 citationsRead the open copy →
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Hiddo J.L. Heerspink, Naveed A. Sattar, Imre J. Pavo et al. · The Lancet Diabetes & Endocrinology · 2022
Randomized trial · Phase 3Open access306 citationsRead the open copy →
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min, Stephen Charles Bain · Diabetes Therapy · 2020
ReviewOpen access · CC BY-NC287 citationsRead the open copy →
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos et al. · Diabetologia · 2022
Meta-analysisOpen access · CC BY273 citationsRead the open copy →
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
Tim Heise, Andrea Mari, J. H. de Vries et al. · The Lancet Diabetes & Endocrinology · 2022
Randomized trial · Phase 1268 citations
- GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms, Michael E. Christe, Kyla A.L. Collins et al. · Journal of Clinical Investigation · 2021
Animal studyOpen access257 citationsRead the open copy →
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Stephen James Nicholls, Deepak L. Bhatt, John B. Buse et al. · American Heart Journal · 2023
Study in humansOpen access · CC BY249 citationsRead the open copy →
- Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura et al. · The Lancet Diabetes & Endocrinology · 2022
Randomized trial · Phase 3Open access227 citationsRead the open copy →
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Stephen James Nicholls, Imre J. Pavo, Deepak L. Bhatt et al. · New England Journal of Medicine · 2025
Clinical trial · Phase 3Open access226 citationsRead the open copy →
- Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Tim Heise, J. Hans DeVries, Shweta Urva et al. · Diabetes Care · 2023
Randomized trialOpen access210 citationsRead the open copy →
- Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda, Jinal Ajabiya, Divya Teli et al. · Molecules · 2022
ReviewOpen access · CC BY208 citationsRead the open copy →
- Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
Juan P. Frías, Michael Albrecht Nauck, Joanna T Van et al. · Diabetes Obesity and Metabolism · 2020
Randomized trialOpen access · CC BY-NC208 citationsRead the open copy →
- Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
Christopher M. Kramer, Barry A. Borlaug, Michael R. Zile et al. · Journal of the American College of Cardiology · 2024
Randomized trialOpen access · CC BY-NC-ND190 citationsRead the open copy →
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
Michelle Look, Julia P. Dunn, Robert F. Kushner et al. · Diabetes Obesity and Metabolism · 2025
Randomized trial · Phase 3Open access · CC BY-NC-ND181 citationsRead the open copy →
- The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Jonathan Matthew Wilson, Amir Nikooienejad, Deborah A. Robins et al. · Diabetes Obesity and Metabolism · 2020
Randomized trialOpen access · CC BY-NC-ND164 citationsRead the open copy →
- Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Ryan J. Jalleh, Mark Philip Plummer, Chinmay S. Marathe et al. · The Journal of Clinical Endocrinology & Metabolism · 2024
ReviewOpen access · CC BY158 citationsRead the open copy →
- Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes
Julio Rosenstock, Juan P. Frías, Helena W. Rodbard et al. · JAMA · 2023
Randomized trial · Phase 3Open access157 citationsRead the open copy →
- Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
Barry A. Borlaug, Michael R. Zile, Christopher M. Kramer et al. · Nature Medicine · 2024
Randomized trialOpen access · CC BY155 citationsRead the open copy →
- Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Fatima Quddos, Zachary Hubshman, Allison N. Tegge et al. · Scientific Reports · 2023
Study in humansOpen access · CC BY151 citationsRead the open copy →
- Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
Fenghui Zhao, Qingtong Zhou, Zhaotong Cong et al. · Nature Communications · 2022
Study in humansOpen access · CC BY149 citationsRead the open copy →
LatestName in title or abstract
- Childhood Obesity And Incretin Therapies With GLP-1 And GIP Receptor Agonists: Efficacy, Safety, And Prospects For Semaglutide And Tirzepatide In Children And Adolescents
Larissa Lauretto, VITOR DACIO MEDEIROS, Vitória de Almeida Rolim Rabelo et al. · Journal of diabetology research. · 2026
Open access · CC BYRead the open copy →
- Tirzepatide and Obstructive Sleep Apnea: Emerging Evidence and Evolving Treatment Strategies
Hyeyun Kim · Journal of the Korean Neurological Association · 2026
Open accessRead the open copy →
- Tirzepatide-associated severe euvolemic hyponatremia with syndrome of inappropriate antidiuretic hormone secretion-compatible biochemical features
Nithin Tumkur Prasad · Indian Journal of Pharmacology · 2026
Case reportOpen access · CC BY-NC-NDRead the open copy →
- The pharmacological frontier in obstructive sleep apnoea: From pathophysiologic endotypes to precision medicine
Hemant Kumar, Anurag Tripathi, Sulakshana Gautam et al. · Lung India · 2026
Open access · CC BY-NC-NDRead the open copy →
- Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes
Hideyuki Okuma · Diabetology International · 2026
Open access · CC BYRead the open copy →
- Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access
Yara E. Tovar, John Yoonkeun Jun · Journal of Health Care for the Poor and Underserved · 2026
Case report
- Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide
顏江河, Guangting Zeng · JACC Advances · 2026
Open access · CC BYRead the open copy →
- Glucagon-Like Peptide-1 Analog–Type Amyloidosis: A Case Report and Review of the Literature
John Loggie, Robert C. McKay, Samih H. Nasr et al. · American Journal of Dermatopathology · 2026
- EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW
Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026
ReviewOpen accessRead the open copy →
- Combined time‐restricted feeding and resistance training enhance tirzepatide‐induced improvements in adiposity and whole‐body insulin sensitivity in female mice
Ana Paula Azevêdo Macêdo, Luciana Renata da Conceição de Mattis, Robson Damasceno de Lima et al. · The Journal of Physiology · 2026
Open accessRead the open copy →
- Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
Turgay Arslan · Endocrine · 2026
Study in humans
- Early Treatment Trajectory and Long‐Term Persistence to Semaglutide for Obesity: A Population‐Based Cohort Study
Eitan Winter, Yael Wolff Sagy, Orna Reges et al. · Diabetes Obesity and Metabolism · 2026
Open accessRead the open copy →
- Changes in Sexual Function and Sexual Quality of Life During GLP-1–Based Therapy in Premenopausal Women with Obesity
Hazel Demiröz Öztürk, Yusuf Öztürk · Medicina · 2026
Open access · CC BYRead the open copy →
- Effects of tirzepatide on brain dopaminergic function in alcohol use disorder: protocol for a randomized, double-blind, crossover PET/MRI study
Nora D. Volkow, D. Tomasi, L. R. Brucar et al. · BMC Psychiatry · 2026
Open access · CC BYRead the open copy →
- Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses
Eyal Schwartzberg, Erez Berman, Segev Shani et al. · Expert Opinion on Pharmacotherapy · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- Prometheus’s Fire, Part III: The Forge of Hephaestus—Non-Pharmacological and Pharmacological Interventions Targeting Adipose Tissue Immunometabolism in Obesity
Anna Grudniewska, Beata Mrozikiewicz‐Rakowska, Kacper Wiszniewski et al. · International Journal of Molecular Sciences · 2026
Open access · CC BYRead the open copy →
- Tirzepatide Versus Semaglutide in Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes: A Target Trial Emulation Study
John W. Ostrominski, Janinne Ortega-Montiel, Wajd Alkabbani et al. · Diabetes Obesity and Cardiometabolic CARE · 2026
- Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Jingyi Zhang, 王永健, Jinjin Li et al. · Drugs · 2026
Systematic review
- Short-Term Glycemic Response to Tirzepatide According to Prior Incretin Therapy in Patients with Type 2 Diabetes Mellitus
Daichi Yamamori, Takashi Kitao, Sachiko Masuda et al. · Cureus · 2026
Open access · CC BYRead the open copy →
- Comparação entre Tirzepatida e Semaglutida na redução de peso em pacientes adultos com obesidade: uma revisão integrativa da literatura
Karine Thamires Witt, Antônio Carlos Mattar Munhoz, Isabela Hoefel Martins et al. · Revista de Medicina UNC · 2026
Open access · CC BY-NDRead the open copy →
- EFEITO DA TIRZEPATIDA NO ESVAZIAMENTO GÁSTRICO: IMPACTO AGUDO VERSOS USO PROLONGADO – REVISÃO SISTEMÁTICA
Alexandre de Souza Soares Júnior, Angelina Fagionato, Bianca Yukari Ito et al. · Brazilian Journal of Health Review · 2026
Open accessRead the open copy →
- Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12‐Month Real‐World Results
Chanadda Chinthammit, Theresa M. Hunter, Melody S. Dehghan et al. · Diabetes Obesity and Metabolism · 2026
Open access · CC BY-NCRead the open copy →
- Perianal Abscesses During Tirzepatide Treatment: A Report of Two Cases
Onur Ekşi, Merve Soyhan · Cureus · 2026
Open access · CC BYRead the open copy →
- Early Body-Composition Trajectory During Tirzepatide Treatment for Obesity: A Real-World Bioimpedance Cohort Study
Enes ZAFER, Deniz Çekiç, Ahmed Bilal Genç et al. · Journal of Clinical Medicine · 2026
Open access · CC BYRead the open copy →
- Oral Health–Related Adverse Events of GLP-1 Receptor Agonists
F.C. Massarotto, A.H. Mahmoud, G.E. Watson et al. · JDR Clinical & Translational Research · 2026
Open accessRead the open copy →
- Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study
Zorba Blázquez‐Bermejo, Daniel Enríquez-Vázquez, Elena García‐Romero et al. · Transplantation · 2026
- Pharmacomicrobiomics of GLP-1 receptor agonist gastrointestinal tolerability: integrating host genetics and the gut microbiome
Shreyas V. Kumbhare, Inti Pedroso, Ranjan Sinha et al. · Frontiers in Microbiomes · 2026
Open access · CC BYRead the open copy →
- TIRZEPATIDA NO MANEJO DA OBESIDADE: REVISÃO INTEGRATIVA
Larissa Lacerda Lodonio, David Nilson Gondim Alves, Rodrigo Toscano de Brito et al. · Revista Destaques Acadêmicos · 2026
Open access · CC BY-NCRead the open copy →
- Interpreting Diabetic Retinal Outcomes After GLP ‐1 Receptor Agonist and Tirzepatide Initiation: Clinical Evidence and Its Limits
Ben Wu, Bin‐Sheng He · Diabetes Obesity and Metabolism · 2026
ReviewOpen accessRead the open copy →
- GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection
Thales Rossatto, Ricardo de Andrade Oliveira, Andréia Machado Cardoso · Diabetes Obesity and Metabolism · 2026
ReviewOpen access · CC BYRead the open copy →
- Tirzepatide (Mounjaro)
CDA-AMC · Canadian Journal of Health Technologies · 2026
Open accessRead the open copy →
- Characteristics and Treatment Utilisation Patterns of Individuals Using Tirzepatide for Type 2 Diabetes in Germany
Martin Füchtenbusch, Marius Kraus, Elke Heitmann et al. · Advances in Therapy · 2026
Open access · CC BY-NCRead the open copy →
- GLP-1 receptor agonist–associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis
Keri Morgan Cronin, Amy Tiersten · Breast Cancer Research and Treatment · 2026
Study in humans
- Beyond glycemic control: emerging therapeutic applications of GLP-1 receptor agonists: a comprehensive narrative review
Nidhi Srivastava, Siddhant Mehrotra, Shubham Biswas et al. · International Journal of Basic & Clinical Pharmacology · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity
Het Tushar Jani, Helisse Levine, Abhiraj Patel et al. · Rambam Maimonides Medical Journal · 2026
ReviewOpen access · CC BYRead the open copy →
- Glucagon-like Peptide-1 Receptor Agonists Promote Sympathetic Innervation in Mouse Adipose Tissues
Koukou Fu, Zhangyuzi Deng, Wenjing Wu et al. · Metabolites · 2026
Open access · CC BYRead the open copy →
- Symptom improvement was not significantly associated with weight loss, dose, or treatment duration in women with lipoedema treated with tirzepatide: a retrospective cohort study of prospectively collected outcomes
Diogo Pinto da Costa Viana, Adriana Luckow Invitti, Eduardo Schor · Metabolism Open · 2026
Open access · CC BYRead the open copy →
- Association between tirzepatide use and risk of suicidal ideation among individuals with obesity and major depressive disorder
Ting-Hui Liu, Chia-Chun Chu, Chia-Yu Liu et al. · Translational Psychiatry · 2026
Open access · CC BY-NC-NDRead the open copy →
- Clinical course and tolerability of glucagon-like peptide-1 receptor agonists in ocular inflammatory disease
Aubrey Nguyen, Negin Yavari, Osama Elaraby et al. · Journal of Ophthalmic Inflammation and Infection · 2026
Open access · CC BYRead the open copy →
- Practical Challenges of Switching and Cross-Titration Between Incretin-Based Therapies in Type 2 Diabetes and Obesity: A Narrative Review
Jana Makuc, Miodrag Janić · Journal of Clinical Medicine · 2026
ReviewOpen access · CC BYRead the open copy →
Each list shows up to 40 papers.See all 4,040 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:30 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.